Log in

Veru Stock Price, Forecast & Analysis (NASDAQ:VERU)

$1.91
+0.02 (+1.06 %)
(As of 11/20/2019 08:55 AM ET)
Today's Range
$1.89
Now: $1.91
$1.94
50-Day Range
$1.87
MA: $2.03
$2.15
52-Week Range
$1.18
Now: $1.91
$2.49
Volume52,500 shs
Average Volume96,832 shs
Market Capitalization$124.23 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. Read More…

Industry, Sector and Symbol

Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
Current SymbolNASDAQ:VERU
CUSIP31446210
Phone305-509-6897

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.86 million
Book Value$0.53 per share

Profitability

Net Income$-23,930,000.00

Miscellaneous

Employees171
Market Cap$124.23 million
Next Earnings Date12/12/2019 (Estimated)
OptionableOptionable

Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.


Veru (NASDAQ:VERU) Frequently Asked Questions

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.00. The business earned $9.73 million during the quarter, compared to analyst estimates of $8.11 million. Veru had a negative net margin of 59.68% and a negative return on equity of 50.14%. View Veru's Earnings History.

When is Veru's next earnings date?

Veru is scheduled to release their next quarterly earnings announcement on Thursday, December 12th 2019. View Earnings Estimates for Veru.

What price target have analysts set for VERU?

6 Wall Street analysts have issued 12-month price objectives for Veru's shares. Their forecasts range from $4.50 to $12.00. On average, they anticipate Veru's share price to reach $6.42 in the next twelve months. This suggests a possible upside of 236.0% from the stock's current price. View Analyst Price Targets for Veru.

What is the consensus analysts' recommendation for Veru?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veru.

What are Wall Street analysts saying about Veru stock?

Here are some recent quotes from research analysts about Veru stock:
  • 1. According to Zacks Investment Research, "Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. " (10/12/2019)
  • 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $300M. This includes a discounted cash flow-based asset value of $310M for FC2 and TADFIN, excluding $10M debt and using a 15% discount rate, 0% terminal growth rate and 80% probability of success for TADFIN. Risks include, but are not limited to: (1) failure of FC2 or TADFIN to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of TADFIN to obtain regulatory approval; (3) failure of other pipeline candidates; and (4) potential dilution risk." (8/9/2019)

Has Veru been receiving favorable news coverage?

Media coverage about VERU stock has trended very positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Veru earned a media sentiment score of 3.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Veru.

Are investors shorting Veru?

Veru saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 63,000 shares, a decrease of 12.6% from the September 30th total of 72,100 shares. Based on an average trading volume of 93,900 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.1% of the company's stock are sold short. View Veru's Current Options Chain.

Who are some of Veru's key competitors?

What other stocks do shareholders of Veru own?

Who are Veru's key executives?

Veru's management team includes the folowing people:
  • Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)
  • Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)
  • Mr. O. B. Parrish, Co-Founder & Director (Age 86)
  • Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)
  • Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51)

Who are Veru's major shareholders?

Veru's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Tower Research Capital LLC TRC (0.02%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View Institutional Ownership Trends for Veru.

Which major investors are buying Veru stock?

VERU stock was bought by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC . Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View Insider Buying and Selling for Veru.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $1.91.

How big of a company is Veru?

Veru has a market capitalization of $124.23 million and generates $15.86 million in revenue each year. The company earns $-23,930,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Veru employs 171 workers across the globe.View Additional Information About Veru.

What is Veru's official website?

The official website for Veru is http://www.veruhealthcare.com/.

How can I contact Veru?

Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected]


MarketBeat Community Rating for Veru (NASDAQ VERU)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel